Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anacor Pharmaceuticals has dosed first patient in a Phase 2b trial of AN2728, a topical anti-inflammatory product candidate for the treatment of psoriasis.
Subscribe to our email newsletter
AN2728 is a boron-based small-molecule compound which inhibits the activity of phosphodiesterase-4 (PDE4), thereby reducing the generation of pro-inflammatory cytokines that are the precursors of the inflammation associated with psoriasis.
The double-blind, randomised, vehicle-controlled is designed to evaluate the safety and efficacy of AN2728 in patients with mild to moderate plaque-type psoriasis.
The trial will enroll 60 patients who will be randomised to 2% AN2728 topical ointment or vehicle in a 2:1 ratio.
The trial will determine the size and design of the two planned pivotal Phase 3 trials of AN2728.
Anacor also reported results from its Phase 1 absorption trial of AN2728, which evaluated the topical pharmacokinetics, systemic safety, and local tolerability of 2% AN2728 ointment in 16 healthy volunteers.
The trial showed that 2% AN2728 topical ointment was well-tolerated and provided a substantial margin of safety for both acute and chronic effects.